thiazoles has been researched along with Minimal Disease, Residual in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burger, JA; Challagundla, P; Champlin, RE; Cortes, JE; Estrov, Z; Faderl, S; Ferrajoli, A; Garris, R; Huang, X; Jorgensen, JL; Kantarjian, HM; Kebriaei, P; Luthra, R; O'Brien, S; Ravandi, F; Thomas, DA; Wang, SA; Wen, S | 1 |
| Bhojwani, D; Campana, D; Cheng, C; Choi, JK; Coustan-Smith, E; Howard, SC; Inaba, H; Jacobsen, J; Jeha, S; Metzger, ML; Pei, D; Pui, CH; Raimondi, S; Ribeiro, RC; Rubnitz, JE; Sandlund, JT; Shurtleff, SA | 1 |
| Akimoto, S; Goto, H; Ishibashi, T; Kiyokawa, N; Kobayashi, K; Kojima, Y; Matsumoto, K; Matsuoka, M; Mitsui, K; Miyagawa, N; Nagai, J; Ohara, A; Okada, Y; Okita, H; Ootsubo, K; Sultana, S; Takahashi, H; Ueno, H | 1 |
| Chen, XJ; Guo, Y; Liu, F; Liu, TF; Ruan, M; Wang, SC; Yang, WY; Zhang, L; Zhu, XF; Zou, Y | 1 |
| Gruber, F; Mustjoki, S; Porkka, K | 1 |
| Czyz, A; Komarnicki, M; Kroll, R; Lewandowski, K | 1 |
| Ottmann, OG; Pfeifer, H | 1 |
| Annunziata, M; Breccia, M; Camera, A; Cavazzini, F; Gozzini, A; Isidori, A; Montefusco, E; Morra, E; Piccaluga, PP; Pregno, P; Santini, V; Specchia, G; Stagno, F; Usala, E; Visani, G | 1 |
| Bartley, PA; Goyne, J; Grigg, AP; Morley, AA; Ross, DM; Seymour, JF | 1 |
| Kantarjian, H; Liu-Dumlao, T; O'Brien, S; Ravandi, F; Thomas, DA | 1 |
| Chen, HC; Hwang, WL; Teng, CL; Yu, JT | 1 |
2 review(s) available for thiazoles and Minimal Disease, Residual
| Article | Year |
|---|---|
Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Combined Modality Therapy; Dasatinib; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transplantation Conditioning; Treatment Outcome | 2009 |
Philadelphia-positive acute lymphoblastic leukemia: current treatment options.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Imidazoles; Neoplasm, Residual; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinolines; Stem Cell Transplantation; Thiazoles | 2012 |
9 other study(ies) available for thiazoles and Minimal Disease, Residual
| Article | Year |
|---|---|
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Flow Cytometry; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoglobulin Heavy Chains; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Thiazoles; Vincristine; Young Adult | 2013 |
Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Dasatinib; Drug Administration Schedule; Female; Flow Cytometry; Genes, T-Cell Receptor; Humans; Imatinib Mesylate; Induction Chemotherapy; Infant; Male; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation.
Topics: Child; Dasatinib; Humans; Male; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Repressor Proteins; Thiazoles; Transcription Factors; Translocation, Genetic | 2015 |
[Efficacy and safety of tyrosine kinase inhibitor dasatinib plus chemotherapy in the treatment of childhood Philadelphia chromosome-positive acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Dasatinib; Female; Humans; Male; Molecular Targeted Therapy; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2015 |
Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Middle Aged; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Thiazoles; Transplantation, Autologous | 2010 |
Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System; Child; Combined Modality Therapy; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemic Infiltration; Mutation; Neoplasm Proteins; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Secondary Prevention; Thiazoles; Transplantation Conditioning | 2009 |
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Italy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction; Retrospective Studies; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult | 2010 |
Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features.
Topics: Adult; Dasatinib; Female; Genes, abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; RNA, Messenger; RNA, Neoplasm; Thiazoles | 2011 |
Maintenance therapy with dasatinib after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Combined Modality Therapy; Dasatinib; Drug Evaluation; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Thiazoles; Transplantation, Homologous | 2013 |